Why Myriad Genetics (MYGN) Stock Hit a One-Year High Today

NEW YORK (TheStreet) -- Myriad Genetics  (MYGN) rose more than 15% to a one-year high of $40.33 as of 10:50 a.m. on Wednesday after the molecular diagnostic company updated its pricing for the sequencing of the BRCA1 and BRCA2 genes.

The new pricing resulted in an increase in the total reimbursement amount for Myriad's integrated BRACAnalysis to $2,767 from $2,021. The BRACAnalysis test determines a woman's risk of developing hereditary breast or ovarian cancer based on mutation detection in the BRCA1 and BRCA2 genes.

Myriad plunged in mid-March after a judge denied Myriad's injunction request against Ambry Genetics. Myriad claimed Ambry's testing services infringed on several patent claims owned by the BRCA patent owners tied to the BRCA1 and BRCA2 genes. Myriad wanted an injunction to stop Ambry from selling the testing services. 

Must Read: Warren Buffett's 10 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MYGN Chart

MYGN data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Stocks Tumble as Dow Heads for Eighth Straight Drop

Stocks Tumble as Dow Heads for Eighth Straight Drop

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Mesoblast Soars on Stem-Cell Treatment Data

Mesoblast Soars on Stem-Cell Treatment Data

Trade Tussle Sinks Stocks, Oil Slides, Micron, Daimler - 5 Things You Must Know

Trade Tussle Sinks Stocks, Oil Slides, Micron, Daimler - 5 Things You Must Know

Bank of England Holds Rates Steady, But Vote Shift Signals Hawkish Tone

Bank of England Holds Rates Steady, But Vote Shift Signals Hawkish Tone